2. Academic Validation
  3. Regulation of eDHFR-tagged proteins with trimethoprim PROTACs

Regulation of eDHFR-tagged proteins with trimethoprim PROTACs

  • Nat Commun. 2023 Nov 3;14(1):7071. doi: 10.1038/s41467-023-42820-3.
Jean M Etersque # 1,  Iris K Lee # 1,  Nitika Sharma # 1,  Kexiang Xu 1,  Andrew Ruff 1,  Justin D Northrup 1,  Swarbhanu Sarkar 1,  Tommy Nguyen 1,  Richard Lauman 2,  George M Burslem 2 3,  Mark A Sellmyer 4 5
Affiliations

Affiliations

  • 1 Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • 2 The Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • 3 The Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • 4 Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. mark.sellmyer@pennmedicine.upenn.edu.
  • 5 The Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. mark.sellmyer@pennmedicine.upenn.edu.
  • # Contributed equally.
PMID: 37923771 DOI: 10.1038/s41467-023-42820-3
Abstract

Temporal control of protein levels in cells and living Animals can be used to improve our understanding of protein function. In addition, control of engineered proteins could be used in therapeutic applications. PRoteolysis-TArgeting Chimeras (PROTACs) have emerged as a small-molecule-driven strategy to achieve rapid, post-translational regulation of protein abundance via recruitment of an E3 Ligase to the target protein of interest. Here, we develop several PROTAC molecules by covalently linking the Antibiotic trimethoprim (TMP) to pomalidomide, a ligand for the E3 Ligase, Cereblon. These molecules induce degradation of proteins of interest (POIs) genetically fused to a small protein domain, E. coli dihydrofolate reductase (eDHFR), the molecular target of TMP. We show that various eDHFR-tagged proteins can be robustly degraded to 95% of maximum expression with PROTAC molecule 7c. Moreover, TMP-based PROTACs minimally affect the expression of immunomodulatory imide drug (IMiD)-sensitive neosubstrates using proteomic and biochemical assays. Finally, we show multiplexed regulation with another known degron-PROTAC pair, as well as reversible protein regulation in a rodent model of metastatic Cancer, demonstrating the formidable strength of this system. Altogether, TMP PROTACs are a robust approach for selective and reversible degradation of eDHFR-tagged proteins in vitro and in vivo.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z